Medshine Discovery Inc.

Zhuhai United Laboratories Co., Ltd.

Cstone Pharmaceuticals

Cstone Pharmaceuticals (shanghai) Co., Ltd.

Cstone Pharmaceuticals (suzhou) Co., Ltd.

Kpc Pharmaceuticals, Inc.

Guangdong Zhongsheng Pharmaceutical Co., Ltd

Cisen Pharmaceutical Co., Ltd.

Guangzhou Joyo Pharmatech Co., Ltd.

Cstone Pharmaceutical (suzhou) Co., Ltd.

Novaonco Js Therapeutics Co., Ltd.

Cstone Pharmaceuticals Co., Ltd.

Changqing Wei

Shuhui Chen

Wenyuan Qian

Jian Li

Yonggang Liao

Hao Wu

Yao Xiao

Guoping Hu

Weiwei Mao

Chen Zhang

Jun Lin

Qiang Guo

Xuejian Zheng

Zhengying Xi

Chaonan Liu

Bin Liu

Chaofeng Long

Xiaoxin Chen

Zhuowei Liu

Zhen Gong

Lijuan Chen

Peng Yu

Lili Fan

Liang Fang

Liwei Mu

Yaxian Cai

Yunhui Li

Bao Yue

Guifen Zhang

The present invention discloses the crystal forms as a JAK inhibitor and their application in the preparation of drugs for the treatment of JAK1 or/and TYK2 related diseases.

Crystalline form of JAK inhibitor and application thereof

Disclosed in the present invention is a series of dimethylsulfoximine derivatives, and specifically disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.

Dimethylsulfoximine derivative

A salt form and crystal form of a mutant IDHI inhibitor and a preparation method therefor.

Salt form and crystal form of mutant IDH1 inhibitor and preparation method therefor

The present invention relates to a pyrrolopyrimidine compound used as a JAK inhibitor, and the use thereof in the preparation of a drug for treating a JAK1- and/or JAK2-associated disease, and in specifically relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Pyrrolopyrimidine compound and use thereof

Disclosed are a [1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and an application thereof in preparing a drug for treating a disease related to JAK1 or/and TYK2. Specifically, the present invention relates to a compound represented by formula (I), or an isomer or pharmaceutically acceptable salt thereof. (I)

[1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and use thereof

Disclosed are a diazaindole derivative as shown in formula I and the use thereof in the preparation of a drug for treating Chk1-related diseases. 

Diazaindole derivative and use thereof as CHK1 inhibitor

Disclosed in the present application are a class of compounds as JAK inhibitors and use thereof in the preparation of medicaments for treating JAK and TYK2 related diseases. Specifically, a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof is disclosed.

JAK inhibitor and use thereof

Disclosed in the present invention are a polymorph A of a compound represented by formula (I), and an application thereof in preparation of drugs for treating HDAC6-associated diseases. 

Polymorph of HDAC6-selective inhibitor and application thereof

A compound as a GLS1 inhibitor as represented by formula (I) or a pharmaceutically acceptable salt thereof. 

Compound as GLS1 inhibitor

Disclosed is to a thiadiazole derivative and the uses thereof in preparing a drug for treating GLS1-associated diseases. Specifically disclosed is a derivative compound of formula (I), a tautomer thereof or a pharmaceutically acceptable composition thereof. 

Substituted 1,3,4-thiadiazoles as GLS1 inhibitors

Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof. 

HDAC6 selective inhibitors, preparation method therefor, and application thereof

Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.

Quinoline derivatives as SMO inhibitors

Growing community of inventors

Shanghai, China

Changqing Wei